Analysts expect Invuity, Inc. (NASDAQ:IVTY) to post sales of $11.84 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Invuity’s earnings, with estimates ranging from $11.60 million to $12.20 million. Invuity posted sales of $9.36 million in the same quarter last year, which suggests a positive year-over-year growth rate of 26.5%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 13th.

On average, analysts expect that Invuity will report full year sales of $11.84 million for the current financial year, with estimates ranging from $40.00 million to $41.10 million. For the next year, analysts anticipate that the company will post sales of $52.70 million per share, with estimates ranging from $50.10 million to $55.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Invuity.

Invuity (NASDAQ:IVTY) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.04. The firm had revenue of $9.60 million for the quarter, compared to analyst estimates of $9.87 million. Invuity had a negative net margin of 111.43% and a negative return on equity of 212.38%.

A number of analysts have recently weighed in on IVTY shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $12.00 price objective on shares of Invuity in a research report on Friday, November 10th. Zacks Investment Research downgraded shares of Invuity from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, Northland Securities reiterated a “buy” rating and set a $13.00 target price on shares of Invuity in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.67.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. CAPROCK Group Inc. boosted its holdings in shares of Invuity by 28.6% in the 3rd quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 10,000 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Invuity during the 2nd quarter worth $101,000. Lyon Street Capital LLC increased its stake in Invuity by 5.2% during the 2nd quarter. Lyon Street Capital LLC now owns 764,530 shares of the medical instruments supplier’s stock worth $5,543,000 after buying an additional 37,498 shares during the period. OxFORD Asset Management LLP purchased a new stake in Invuity during the 2nd quarter worth $374,000. Finally, Vanguard Group Inc. increased its stake in Invuity by 16.3% during the 2nd quarter. Vanguard Group Inc. now owns 402,680 shares of the medical instruments supplier’s stock worth $2,919,000 after buying an additional 56,527 shares during the period. Hedge funds and other institutional investors own 69.00% of the company’s stock.

Shares of Invuity (NASDAQ IVTY) traded down $0.10 during midday trading on Wednesday, reaching $5.30. The company’s stock had a trading volume of 541,282 shares, compared to its average volume of 225,664. The stock has a market capitalization of $92.55 and a price-to-earnings ratio of -2.16. The company has a current ratio of 2.90, a quick ratio of 2.47 and a debt-to-equity ratio of 5.39. Invuity has a 52 week low of $5.15 and a 52 week high of $9.70.

ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Invuity, Inc. (IVTY) Will Post Quarterly Sales of $11.84 Million” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/17/analysts-anticipate-invuity-inc-ivty-will-post-quarterly-sales-of-11-84-million.html.

Invuity Company Profile

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Get a free copy of the Zacks research report on Invuity (IVTY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.